Oct 30 2026 11:04 PM EST

Oct 30 2026 10:00 PM EST

Regulatory wins lift biotech stocks while StoneCo’s dividend rally masks rate‑sensitivity risks

Replimune Group (NASDAQ: REPL) surged after a 10‑3 FDA advisory vote and an accelerated‑approval outlook for its RP1 oncolytic therapy; Prime Medicine (NASDAQ: PRME) jumped on FDA IND clearance for its PM647 gene‑editing program; and StoneCo Ltd. (NASDAQ: STNE) rose on an extraordinary dividend and buy‑back but remains the weakest mover amid higher‑for‑longer Selic‑rate concerns.

Replimune’s shares more than doubled in after‑hours trading after the FDA’s Cellular, Tissue and Gene Therapies Advisory Committee voted 10‑3 in favor of the IGNYTE data package for RP1 + nivolumab in PD‑1‑refractory melanoma, setting the stage for an accelerated‑approval decision slated for August 2 2026. The company reported a FY 2026 net loss of $313.9 million and Q4 2026 EPS of ($0.72), missing consensus of ($0.69). Cash and short‑term investments stood at $268.9 million, funding operations into Q1 2027. Prime Medicine’s stock rose more than 30% after the FDA granted IND clearance for PM647, an in‑vivo Prime Editor targeting the PiZZ genotype of Alpha‑1 Antitrypsin Deficiency; the company holds $108.8 million in cash and expects the Phase 1/2 trial to enroll up to 100,000 carriers. StoneCo reported Q2 2026 revenue of R$3.59 bn (+2.5% YoY) and adjusted EPS of R$2.40 (+8.6% YoY), while announcing a US$2.53 per‑share extraordinary dividend and a new R$2 bn buy‑back authorization.

Biotech Catalysts Power Replimune and Prime Medicine

The FDA advisory committee vote for Replimune removed a key regulatory hurdle for RP1 + nivolumab, and investors interpreted the outcome as a de‑facto green light, driving a more than six‑fold six‑month rally. Management’s cash runway, bolstered by a $150 million public offering (late 2025), a $100 million PIPE (June 2025) and a $250 million securities program (Dec 2025), supports the commercial launch of TUDRIQEV™ at a list price of $450,000 per treatment course. Prime Medicine’s IND clearance for PM647 unlocks a Phase 1/2 trial that could enroll up to 100,000 carriers, positioning the company at the forefront of next‑generation Prime Editing. Its cash balance of $108.8 million is sufficient to fund operations into 2027, despite a quarterly net loss of $42.1 million. Both firms benefit from a broader biotech tailwind of lower interest rates and regulatory incentives such as RMAT and Rare Pediatric Disease designations.

StoneCo’s Capital Returns Highlight Rate‑Sensitivity

StoneCo’s 24.4% five‑day gain was driven by an extraordinary cash dividend of US$2.53 per share and a new R$2 bn share‑buyback programme, raising total 2026 capital returns to R$3.6 bn. However, management warned that the lower end of its 2026 adjusted gross‑profit guidance (R$4.6‑7.0 bn) is more likely as Brazil’s Selic rate is expected to remain “higher‑for‑longer.” The higher‑for‑longer environment raises funding costs for the firm’s credit‑portfolio, which doubled YoY to R$3.8 bn, and could compress margins. Analysts note a forward P/E of roughly 4.4×, a discount to peers that may reflect lingering concerns over credit‑quality risk and fee‑compression from the Pix instant‑payment platform.

The contrasting narratives illustrate a market that rewards clear regulatory milestones in biotech while remaining cautious on financial‑services firms exposed to macro‑rate dynamics. Replimune and Prime Medicine’s stock moves are directly linked to FDA actions that could unlock high‑value revenue streams, whereas StoneCo’s share‑price gain reflects capital‑return announcements that do not fully offset concerns over Brazil’s higher‑for‑longer monetary policy and credit‑portfolio sustainability.

Investors will watch Replimune’s accelerated‑approval decision on August 2 2026 and Prime Medicine’s Phase 1/2 data expected in 2027 for confirmation of upside potential. For StoneCo, the trajectory of Selic rates and the performance of its expanding credit book will determine whether the current rally can translate into longer‑term valuation compression.